The US Food and Drug Administration (FDA) has approved AstraZeneca’s asthma treatment, Airsupra after positive results from a global phase 3 clinical trial.
The not-for-profit organization published its fair inclusion score to measure and rank pharmaceutical companies on their inclusion of women, older adults, and racial and ethnic minoritized patients.
The cryptocurrency space suffered through a torrid, scandal-marked 2022 but there remains interest in using the blockchain infrastructure that underpins the sector in other contexts. In a recent review of the potential of the blockchain in healthcare,...
Digital twins could overcome common data management issues at equipment-intense research facilities, according to a paper published in the journal Sensors.
Turbine will provide its machine learning platform to better understand which cancer types and patient population stand to benefit most from treatment by Cancer Research’s drug candidate.
The health data company emerges promising to revolutionize the real-world data made available to clinical researchers, and to provide the data to the patients themselves.
On Friday (Jan 6), the US Food and Drink Administration (FDA) granted a licence for another anti-amyloid drug – lecanemab – to treat Alzheimer’s disease.
After a successful evaluation of its whole-genome sequencing-based test for solid tumor minimal residual disease (MRD) C2i Genomics announced today (January 5) that they have extended their collaboration with AstraZeneca.
The two companies, who had previously established a customer-supplier relationship, have created an agreement to advance the technology and to encourage adoption.
The partners have come together to apply artificial intelligence to phenotypic drug screening, with the aim of developing therapies in different therapeutics areas.
As the year draws to a close, Outsourcing-Pharma caught up with some senior executives for a three-part series looking back on an eventful 2022, and look ahead to 2023.
Clinical operations digital maturity, capability prioritization, and best practice adoption vary widely at the world’s largest pharma firms, according to a survey of senior leaders at the companies.
Pfizer receives additional orders for its COVID-19 treatment, after US requests more doses, and several Chinese companies are also reported to have begun selling the product.
As the year draws to a close, Outsourcing-Pharma caught up with some senior executives for a three-part series looking back on an eventful 2022, and look ahead to 2023.
Medable and Syneos Health have extended their partnership to leverage the former’s established DCT technology solutions with an aim to expand access to clinical trials.
As the year draws to a close, Outsourcing-Pharma caught up with some senior executives for a three-part series looking back on an eventful 2022, and look ahead to 2023.
Millstone Medical Outsourcing is keeping up the pace of its deal-driven expansion strategy by closing the takeover of regulatory testing services provider Ethide Laboratories.
The company announced Phase III results showing that hemoglobin levels were increased when patients were treated with investigational oral monotherapy, iptacopan.
The company states that the new app is able to cut study start-up times for sponsors and CROs, while it can also be used by patients across various different platforms.
Emergent’s application for its Narcan product to be sold OTC for the treatment of opioid overdose has been accepted by the US FDA and provided priority review.
CordenPharma joins global science initiative SBTi and announces commitment to ambitious reduction in greenhouse gas emissions in alignment with the Paris agreement.
BioNTech and Ryvu Therapeutics will collaborate to develop oncology programs, with the pair announcing that they will work together as part of a multi-target research collaboration.
PureTech plans to take LYT-310 into the clinic, with the expectation that an oral capsule form of delivery could prove more effective than oil-based formulations.
The Chinese company reveals a new parenteral formulation manufacturing line has begun operations, and that it has signed a deal for the deployment of a robotic system for oral solid dosage forms.
Experic raises $14m in series B led by Harro Hofilger Packaging Systems and East Seattle Partners as CDMO sees growth in DPI product and clinical trial supply needs.
The CRO focuses its services towards biotechs by stating that they are cheaper and more efficient compared to rivals, and it was this principle that drew in General Catalyst to provide investment.
ALS genetic carrier finds value in EverythingALS study leveraging digital biomarkers as a means to create tools for early detection of ALS and potentially other neurological diseases.
